Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clare Y Slaney

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Autoimmunity|February 5, 2013
A modified superantigen rescues Ly6G- CD11b+ blood monocyte suppressor function and suppresses antigen-specific inflammation in EAEClare Y Slaney, Aras Toker, John D Fraser, et al.
The FEBS Journal|April 6, 2020
Cross-talk between tumors at anatomically distinct sitesAmanda J Oliver, Phillip K Darcy, Joseph A Trapani, et al.
Immunotherapy|June 13, 2015
Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppressionPaul A Beavis, Clare Y Slaney, Michael H Kershaw, et al.
Nature Reviews. Immunology|April 21, 2021
Cellular networks controlling T cell persistence in adoptive cell therapyJack D Chan, Junyun Lai, Clare Y Slaney, et al.
Molecular Immunology|January 18, 2015
Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinicConnie P M Duong, Carmen S M Yong, Michael H Kershaw, et al.
Seminars in Immunology|November 28, 2015
Reprogramming the tumor microenvironment to enhance adoptive cellular therapyPaul A Beavis, Clare Y Slaney, Michael H Kershaw, et al.
Frontiers in Oncology|February 28, 2019
Genetic Redirection of T Cells for the Treatment of Pancreatic CancerAesha I Ali, Amanda J Oliver, Tinaz Samiei, et al.
Frontiers in Immunology|February 16, 2018
Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy ResponsesAmanda J Oliver, Peter K H Lau, Ashleigh S Unsworth, et al.
Oncoimmunology|October 10, 2015
CD73: A potential biomarker for anti-PD-1 therapyPaul A Beavis, Clare Y Slaney, Nicole Milenkovski, et al.
Journal for Immunotherapy of Cancer|May 26, 2021
Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapiesDaniela Gm Tantalo, Amanda J Oliver, Bianca von Scheidt, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Autoimmunity|February 5, 2013
A modified superantigen rescues Ly6G- CD11b+ blood monocyte suppressor function and suppresses antigen-specific inflammation in EAEClare Y Slaney, Aras Toker, John D Fraser, et al.
The FEBS Journal|April 6, 2020
Cross-talk between tumors at anatomically distinct sitesAmanda J Oliver, Phillip K Darcy, Joseph A Trapani, et al.
Immunotherapy|June 13, 2015
Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppressionPaul A Beavis, Clare Y Slaney, Michael H Kershaw, et al.
Nature Reviews. Immunology|April 21, 2021
Cellular networks controlling T cell persistence in adoptive cell therapyJack D Chan, Junyun Lai, Clare Y Slaney, et al.
Molecular Immunology|January 18, 2015
Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinicConnie P M Duong, Carmen S M Yong, Michael H Kershaw, et al.
Seminars in Immunology|November 28, 2015
Reprogramming the tumor microenvironment to enhance adoptive cellular therapyPaul A Beavis, Clare Y Slaney, Michael H Kershaw, et al.
Frontiers in Oncology|February 28, 2019
Genetic Redirection of T Cells for the Treatment of Pancreatic CancerAesha I Ali, Amanda J Oliver, Tinaz Samiei, et al.
Frontiers in Immunology|February 16, 2018
Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy ResponsesAmanda J Oliver, Peter K H Lau, Ashleigh S Unsworth, et al.
Oncoimmunology|October 10, 2015
CD73: A potential biomarker for anti-PD-1 therapyPaul A Beavis, Clare Y Slaney, Nicole Milenkovski, et al.
Journal for Immunotherapy of Cancer|May 26, 2021
Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapiesDaniela Gm Tantalo, Amanda J Oliver, Bianca von Scheidt, et al.
Pageof 4